Allogene Therapeutics Inc.

16.57+0.3700+2.28%Vol 2.29M1Y Perf -23.76%
Aug 11th, 2022 16:00 DELAYED
BID16.01 ASK16.60
Open16.24 Previous Close16.20
Pre-Market- After-Market16.90
 - -  0.33 1.99%
Target Price
25.36 
Analyst Rating
Strong Buy 1.50
Potential %
53.05 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-79 
Value Ranking
★★★+     54.42
Insiders Value % 3/6/12 mo.
-100/-100/7 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/9 
Income Ranking
 —    -
Price Range Ratio 52W %
47.33 
Earnings Rating
Strong Buy
Market Cap2.38B 
Earnings Date
9th Aug 2022
Alpha-0.00 Standard Deviation0.20
Beta0.49 

Today's Price Range

15.7317.18

52W Range

6.4327.86

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
7.18%
1 Month
42.84%
3 Months
137.73%
6 Months
63.25%
1 Year
-23.76%
3 Years
-43.81%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLO16.570.37002.28
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-147 602.00
-141 637.00
-
-
RevenueValueIndustryS&P 500US Markets
161.00K
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.61-0.5214.75
Q01 2022-0.59-0.565.08
Q04 2021-0.61-0.5411.48
Q03 2021-0.56-0.57-1.79
Q02 2021-0.55-0.533.64
Q01 2021-0.48-0.2547.92
Q04 2020-0.56-0.535.36
Q03 2020-0.55-0.525.45
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.613.17Positive
9/2022 QR-0.670.00-
12/2022 FY-2.590.77Positive
12/2023 FY-2.96-3.14Negative
Next Report Date-
Estimated EPS Next Report-0.61
Estimates Count11
EPS Growth Next 5 Years %-
Volume Overview
Volume2.29M
Shares Outstanding143.81K
Shares Float89.61M
Trades Count25.23K
Dollar Volume37.95M
Avg. Volume1.89M
Avg. Weekly Volume2.06M
Avg. Monthly Volume1.61M
Avg. Quarterly Volume2.00M

Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 16.57 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 2.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 265 people. Allogene Therapeutics Inc. CEO is David D. Chang.

The one-year performance of Allogene Therapeutics Inc. stock is -23.76%, while year-to-date (YTD) performance is 11.06%. ALLO stock has a five-year performance of %. Its 52-week range is between 6.425 and 27.86, which gives ALLO stock a 52-week price range ratio of 47.33%

Allogene Therapeutics Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 2.15, a price-to-sale (PS) ratio of 11 149.10, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.35%, a ROC of -29.87% and a ROE of -31.57%. The company’s profit margin is -%, its EBITDA margin is -141 637.00%, and its revenue ttm is $161.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allogene Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Strong Buy (1.5), with a target price of $25.36, which is +53.05% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.72, ATR14 : 1.20, CCI20 : 179.73, Chaikin Money Flow : 0.19, MACD : 1.12, Money Flow Index : 66.45, ROC : 22.29, RSI : 54.61, STOCH (14,3) : 88.49, STOCH RSI : 1.00, UO : 67.59, Williams %R : -11.51), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Sold 8 698 shares of value $66 388 ), Arie S. Belldegrun (Buy at a value of $1 953 491), David D. Chang (Sold 23 648 shares of value $180 879 ), Eric Schmidt (Sold 11 469 shares of value $87 551 ), Joshua A. Kazam (Buy at a value of $189 000), Owen N. Witte (Sold 20 000 shares of value $361 500 ), Rafael Amado (Sold 28 176 shares of value $405 125 ), Rafael G. Amado (Sold 32 176 shares of value $450 365 ), Veer Bhavnagri (Option Excercise at a value of $22 700), Veer Bhavnagri (Sold 18 849 shares of value $296 801 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (62.50 %)
10 (71.43 %)
Moderate Buy
2 (12.50 %)
2 (12.50 %)
2 (14.29 %)
Hold
3 (18.75 %)
4 (25.00 %)
2 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Moderate Buy
1.63
Strong Buy
1.43

Allogene Therapeutics Inc.

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

CEO: David D. Chang

Telephone: +1 650 457-2700

Address: 210 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 265

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

79%21%

Bearish Bullish

67%33%

TipRanks News for ALLO

Sat, 05 Mar 2022 09:08 GMT Allogene Therapeutics (ALLO) Gets a Hold Rating from J.P. Morgan

- TipRanks. All rights reserved.

Sun, 27 Feb 2022 10:51 GMT Allogene Therapeutics (ALLO) Gets a Buy Rating from RBC Capital

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 11:25 GMT Allogene Therapeutics (ALLO) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits